Top Markets
#1 MowCat MowCat +48.94%
#2 Bermuda Shorts Bermuda Shorts +25.42%
#3 aPriori aPriori +21.46%
#4 Biconomy Biconomy +19.82%
#5 Derive Derive +19.05%
#6 Velvet Velvet +18.18%
#7 Quack AI Quack AI +17.27%
#8 Audiera Audiera +15.85%
#9 Perle Perle +14.87%
#10 Palladium Network Palladium Network +13.69%
Coin of the day
MowCat MowCat
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
IMV Inc. IMV Inc.

IMV Inc.

IMV
Kedudukan dalam Saham #35289
IMV Inc. is a clinical-stage biotechnology company dedicated to the development... IMV Inc. is a clinical-stage biotechnology company dedicated to the development of innovative immunotherapies. The company utilizes its proprietary DPX immune-educating technology platform to create a portfolio of treatments for various solid and hematological cancers. Its leading investigational drug, maveropepimut-S, is a DPX-based immunotherapy designed to target cancer cells that express survivin. Maveropepimut-S is currently undergoing Phase II clinical trials for diffuse large B-cell lymphoma, ovarian cancer, and specific bladder, liver, and microsatellite instability-high tumors, with Phase I trials also active for breast cancer. Beyond its primary candidate, IMV is also advancing DPX-SurMAGE, which is in Phase I clinical trials for bladder cancer, and is developing DPX-COVID-19 and DPX-RSV to address infectious diseases. Originally founded in 2000 as Immunovaccine Inc., the company adopted the name IMV Inc. in May 2018 and operates from its headquarters in Dartmouth, Canada.
Harga Saham
$0.82959892
Disegerakkan terakhir: 2023-05-23
Modal Pasaran
$4.16M
Perubahan (1 hari)
-0.04%
Perubahan (1 tahun)
0.00%
Negara
CA
Perdagangan IMV Inc. (IMV)

Kategori

Healthcare
Hasil untuk IMV Inc. (IMV)
Hasil pada Aug 2026 TTM: 0
Menurut laporan kewangan terkini daripada IMV Inc., hasil semasa syarikat (TTM) ialah 0. Pada tahun 2026, syarikat memperoleh hasil sebanyak 0 sama dengan hasil pada tahun 2026 iaitu 0. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi IMV Inc. dari 2026 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
Tidak cukup data untuk tarikh yang disediakan.
Hasil untuk syarikat atau pesaing serupa
Syarikat Hasil Perbezaan Hasil Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE